Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Next PCSK-9 Pricing Debate: PBM Says Outcomes Data Should Mean Deeper Discount

Executive Summary

Express Scripts expects to negotiate a lower price per patient for Amgen’s Repatha assuming the drug shows benefits in a 27,500-patient outcomes trial. Critics of the PBM and its practices, however, may help industry push back against the idea that greater benefit means lower prices.


Related Content

Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
The Future Of Specialty Drug Pricing


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts